Contrasting Whitehawk Therapeutics (NASDAQ:WHWK) & Vincerx Pharma (NASDAQ:VINC)

Whitehawk Therapeutics (NASDAQ:WHWK) and Vincerx Pharma (NASDAQ:VINC) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Whitehawk Therapeutics and Vincerx Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	2	0	2.25
Vincerx Pharma	0	0	0	0	0.00

Whitehawk Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 85.19%. Given Whitehawk Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Whitehawk Therapeutics is more favorable than Vincerx Pharma.

Volatility & Risk

Whitehawk Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

Profitability

This table compares Whitehawk Therapeutics and Vincerx Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-68.32%	-63.21%
Vincerx Pharma	N/A	-248.33%	-132.73%

Earnings and Valuation

This table compares Whitehawk Therapeutics and Vincerx Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$25.98 million	6.37	-$63.69 million	$0.14	25.07
Vincerx Pharma	N/A	N/A	-$40.16 million	($5.31)	0.00

Vincerx Pharma has lower revenue, but higher earnings than Whitehawk Therapeutics. Vincerx Pharma is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Whitehawk Therapeutics beats Vincerx Pharma on 10 of the 12 factors compared between the two stocks.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.